Cord blood-derived NK cells engineered with NY-ESO-1 TCR/IL-15 receptor

engineered natural killer cell therapy targeting NY-ESO-1 with IL-15 receptor · The University of Texas MD Anderson Cancer Center

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Cord blood-derived NK cells engineered with NY-ESO-1 TCR/IL-15 receptor, covering 2026-03-11 to 2026-03-11. Get the full timeline:

Most recent: Clinical Trial Update: Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

See pricing